products
products
that
promote healing.
products
that
promote healing.
ECI develops breakthrough products for eye care, wound care, and burn healing that leverage our platelet-rich plasma-derived growth factor and excipient platform to help patients see clearly and live healthier lives.
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. Initially, ECI is pursuing ophthalmic indications for neurotrophic keratopathy (NK) and dry eye disease (DED).
ECI’s pipeline includes indications for ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular graft-versus-host disease (GvHD), corneal abrasions, and chronic wounds.
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.
our patients
Patients who experience conditions ranging from neurotrophic keratitis (NK) to dry eye disease (DED), wounds, or burns may benefit from our fusion of plasma and HA as a forward-thinking and potent strategy to potentially address their conditions with easier access and fewer side effects.
Neurotrophic Keratitis Patients (US)
0
Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation.
It is recognized by the FDA as a rare disease.
Dry Eye Patients (US)
0
There are 22 million dry eye patients in the United States
and of those only 8 million are treated,
with 50% discontinuing treatment, largely due to dissatisfaction.
Neurotrophic Keratitis Patients (US)
0
Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation. It is recognized by the FDA as a rare disease.
Dry Eye Patients (US)
0
There are 22 million dry eye patients in the United States
and of those only 8 million are treated,
with 50% discontinuing treatment, largely due to dissatisfaction.
Neurotrophic Keratitis Patients (US)
0
Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation. It is recognized by the FDA as a rare disease.
Dry Eye Patients (US)
0
There are 22 million dry eye patients in the United States
and of those only 8 million are treated, with 50% discontinuing treatment,
largely due to dissatisfaction.
people
Our team is comprised of experts in blood banking / hematology, ophthalmology, and biomedical/biomaterial engineering.
Interested in joining us on our mission? Learn about our culture and explore opportunities to be part of our story.
We hope you like coffee and puppies!